Early access
Sign in
Active, not recruitingPhase 3

A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

Key facts

Who runs it
Priovant Therapeutics, Inc.
Where
Ann Arbor, Aurora, Austin, Bakersfield, Baltimore, Bellaire, Beverly Hills, Boston, Carmel, Chicago, Cleveland, Columbus, Dallas, Denver, Detroit, Durham, Erie, Fort Lauderdale, Fullerton, Greenville, Houston, Irvine, Katy, La Jolla, Los Angeles, Madison, Minneapolis, Modesto, Nashville, New York, Oak Park, Omaha, Palisades Park, Philadelphia, Phoenix, Plano, Portland, Prairie Village, Rochester, Round Rock, Sacramento, San Antonio, St Louis, St. Petersburg, Waltham, and Winston-Salem, United StatesSee the 46 sitesAlso in 13 other countries, 50 sites
Status
Active, not recruiting
Phase
Phase 3
People taking part
371 people enrolled
Started
11 Sept 2024
Expected to end
1 Feb 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Brepocitinib PO QD
  • Placebo PO QD
Record updated
12 January 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Adult subjects (18-75 years old)
  • Diagnosis of non-infectious uveitis (intermediate uveitis, posterior uveitis, or panuveitis)
  • Active uveitic disease in at least 1 eye
  • Weight > 40 kg with a body mass index ≤ 40 kg/m2

Who cannot take part

  • cancer within 5 years prior to screening (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid carcinoma.)
  • Has confirmed or suspected current diagnosis of infectious uveitis History of or have:
  • Lymphoproliferative disorder
  • active malignancy
  • thrombosis or cerebrovascular ischemic event disease within the last 12 months
  • active or recent infections
  • a high risk for herpes zoster reactivation

Where in United States

Also in 13 other countries, 50 sites

  • Ann Arbor, MichiganHospital not named in the registry
  • Aurora, ColoradoHospital not named in the registry
  • Austin, TexasHospital not named in the registry
  • Bakersfield, CaliforniaHospital not named in the registry
  • Baltimore, MarylandHospital not named in the registry
  • Bellaire, TexasHospital not named in the registry
  • Beverly Hills, CaliforniaHospital not named in the registry
  • Boston, MassachusettsHospital not named in the registry
  • Carmel, IndianaHospital not named in the registry
  • Chicago, IllinoisHospital not named in the registry
  • Cleveland, OhioHospital not named in the registry
  • Columbus, OhioHospital not named in the registry
  • Dallas, TexasHospital not named in the registry
  • Denver, ColoradoHospital not named in the registry
  • Detroit, MichiganHospital not named in the registry
  • Durham, North CarolinaHospital not named in the registry
  • Erie, PennsylvaniaHospital not named in the registry
  • Fort Lauderdale, FloridaHospital not named in the registry
  • Fullerton, CaliforniaHospital not named in the registry
  • Greenville, South CarolinaHospital not named in the registry
  • Houston, TexasHospital not named in the registry
  • Irvine, CaliforniaHospital not named in the registry
  • Katy, TexasHospital not named in the registry
  • La Jolla, CaliforniaHospital not named in the registry
  • Los Angeles, CaliforniaHospital not named in the registry
  • Madison, WisconsinHospital not named in the registry
  • Minneapolis, MinnesotaHospital not named in the registry
  • Modesto, CaliforniaHospital not named in the registry
  • Nashville, TennesseeHospital not named in the registry
  • NYU Langone HealthNew York, United States
  • Oak Park, IllinoisHospital not named in the registry
  • Omaha, NebraskaHospital not named in the registry
  • Palisades Park, New JerseyHospital not named in the registry
  • Philadelphia, PennsylvaniaHospital not named in the registry
  • Phoenix, ArizonaHospital not named in the registry
  • Plano, TexasHospital not named in the registry
  • Portland, OregonHospital not named in the registry
  • Prairie Village, KansasHospital not named in the registry
  • Rochester, MinnesotaHospital not named in the registry
  • Round Rock, TexasHospital not named in the registry
  • Sacramento, CaliforniaHospital not named in the registry
  • San Antonio, TexasHospital not named in the registry
  • St Louis, MissouriHospital not named in the registry
  • St. Petersburg, FloridaHospital not named in the registry
  • Waltham, MassachusettsHospital not named in the registry
  • Winston-Salem, North CarolinaHospital not named in the registry

About the trial

What the trial wants to find out

The purpose of this study is to determine the safety and efficacy of brepocitinib in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).

The 2 groups in the trial

  • Arm 1Treatment being tested

    Treatment: Brepocitinib PO QD

  • Arm 2Placebo, for comparison

    Treatment: Placebo PO QD

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis
Record updated
12 January 2026